California-based Gossamer Bio announced Monday that it is discontinuing the development of its lymphoma candidate GB5121 following two patient deaths in the Phase Ib/II STAR-CNS study.
Tag Archive for: atrial fibrillation
Bayer predicted on Tuesday its experimental drug against dangerous blood clots could make more than 5 billion euros ($5.4 billion) in peak annual sales, as the company seeks to revive a share price that has drawn interest from activist investors.
AbbVie’s investigational neurotoxin, designed to prevent postoperative atrial fibrillation, missed the primary endpoint in a Phase II trial, the company announced Monday.
